JBIO vs ABUS

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 03, 2026

JBIO

55.4
AI Score
VS
JBIO Wins

ABUS

36.2
AI Score

Investment Advisor Scores

JBIO

55score
Recommendation
HOLD

ABUS

36score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric JBIO ABUS Winner
Forward P/E 0 10.2459 Tie
PEG Ratio 0 0 Tie
Revenue Growth 0.0% -90.6% JBIO
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 55.4/100 36.2/100 JBIO
Profit Margin 0.0% 84.2% ABUS
Beta 1.00 1.00 Tie
AI Recommendation HOLD AVOID NEW MONEY JBIO

Relative Price Performance (Last 90 Days)

JBIO 1M: -34.0% · 3M: -33.7% ABUS 1M: -12.7% · 3M: -10.5%

Current Technical Phase

JBIO

Markdown
Sell / avoid

Price below a falling SMA50 (slope -9.1%), weak momentum, RSI 24

RSI (14): 24.2 · Price: $14.12

ABUS

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 28

RSI (14): 28.0 · Price: $4.45

Fundamentals Snapshot

Metric JBIO ABUS
Market Cap — —
Forward P/E -5.3 -40.1
Trailing P/E — 6.1
Revenue (TTM) — —
Revenue Growth 0.0% -0.9%
Gross Margin — 0.9%
Operating Margin 0.0% -5.7%
EPS -1.05 0.75
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, JBIO is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.